Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination With Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma Multiforme

NCT06157541 is registered in ClinicalTrials.gov with Queensland Institute of Medical Research as lead sponsor.

NCT NCT06157541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06157541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination With Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma Multiforme
Lead sponsor
Queensland Institute of Medical Research
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 8, 2024
Completion date
January 31, 2028
Enrollment
58 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, grade iv, glioblastoma multiforme